{
    "clinical_study": {
        "@rank": "122805", 
        "arm_group": [
            {
                "arm_group_label": "metformin", 
                "arm_group_type": "Active Comparator", 
                "description": "In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os."
            }, 
            {
                "arm_group_label": "metformin and roflumilast", 
                "arm_group_type": "Active Comparator", 
                "description": "In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time roflumilast was initiated at a dose of 500 mg BID per os."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study was to determine whether combined treatment with\n      phosphodiesterase-4 (PDE-4) inhibitor roflumilast and metformin is more effective than\n      metformin as monotherapy in the treatment of obese women with polycystic ovary syndrome\n      (PCOS) who had been previously poor responders regarding weight reduction on metformin\n      monotherapy. The investigators anticipated greater changes in body weight in patients on\n      combined treatment than in those on monotherapy with metformin."
        }, 
        "brief_title": "PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "PCOS", 
            "Obesity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Polycystic Ovary Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years old to menopause\n\n          -  polycystic ovary syndrome (NICHD criteria)\n\n          -  BMI of 30 kg/m\u00b2 or higher\n\n        Exclusion Criteria:\n\n          -  depression\n\n          -  type 1 or type 2 diabetes mellitus\n\n          -  history of carcinoma\n\n          -  Cushing's syndrome or congenital (non-classic) adrenal hyperplasia\n\n          -  significant cardiovascular, kidney or hepatic disease\n\n          -  the use of medications other than metformin known or suspected to affect reproductive\n             or metabolic functions\n\n          -  the use of statins, within 90 days prior to study entry"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02037672", 
            "org_study_id": "DAXAS"
        }, 
        "intervention": [
            {
                "arm_group_label": "metformin", 
                "intervention_name": "metformin", 
                "intervention_type": "Drug", 
                "other_name": "Glucophage tablets"
            }, 
            {
                "arm_group_label": "metformin and roflumilast", 
                "intervention_name": "metformin and roflumilast", 
                "intervention_type": "Drug", 
                "other_name": "Glucophage tablets and Daxas 500 micrograms film-coated tablets"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Metformin", 
                "Phosphodiesterase 4 Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "PCOS", 
            "PDE-4 inhibitor", 
            "roflumilast", 
            "metformin", 
            "obesity"
        ], 
        "lastchanged_date": "January 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ljubljana", 
                    "country": "Slovenia", 
                    "zip": "1000"
                }, 
                "name": "University Medical Center Ljubljana"
            }
        }, 
        "location_countries": {
            "country": "Slovenia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Combined Treatment With PDE-4 Inhibitor Roflumilast and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome", 
        "other_outcome": [
            {
                "description": "Patient's blood was drawn between 8 and 9 a.m. Concentrations of fasting glucose was measured in mmol/L.", 
                "measure": "The other outcomes was changes in fasting concentrations of glucose.", 
                "safety_issue": "No", 
                "time_frame": "Patient's fasting blood was drawn at the base point and at the endpoint of 12 weeks of clinical trial."
            }, 
            {
                "description": "Patient's blood was drawn between 8 and 9 a.m. Fasting concentrations of insulin was measured in mU/L.", 
                "measure": "Other outcome was change in fasting concentration of insulin.", 
                "safety_issue": "No", 
                "time_frame": "Patient's fasting blood was drawn at the base point and at the endpoint of 12 weeks of clinical trial."
            }, 
            {
                "description": "Patient's blood was drawn between 8 and 9 a.m. Concentration of LH was measured in U/L.", 
                "measure": "Other outcome was change in blood concentrations of LH (luteinizing hormone).", 
                "safety_issue": "No", 
                "time_frame": "Patient's fasting blood was drawn at the base point and at the endpoint of 12 weeks of clinical trial."
            }, 
            {
                "description": "Patient's blood was drawn between 8 and 9 a.m. Blood concentrations of FSH was measured in U/L.", 
                "measure": "Other outcome was change in blood concentrations of FSH (follicle-stimulating hormone).", 
                "safety_issue": "No", 
                "time_frame": "Patient's fasting blood was drawn at the base point and at the endpoint of 12 weeks of clinical trial."
            }, 
            {
                "description": "Patient's blood was drawn between 8 and 9 a.m. Blood concentration was measured in nmol/L.", 
                "measure": "Other outcome was change in blood concentration of testosterone.", 
                "safety_issue": "No", 
                "time_frame": "Patient's fasting blood was drawn at the base point and at the endpoint of 12 weeks of clinical trial."
            }, 
            {
                "description": "Patient's blood was drawn between 8 and 9 a.m. Blood concentrations of androstenedione was measured in nmol/L.", 
                "measure": "Other outcome was change in blood concentration in androstenedione.", 
                "safety_issue": "No", 
                "time_frame": "Patient's fasting blood was drawn at the base point and at the endpoint of 12 weeks of clinical trial."
            }, 
            {
                "description": "Patient's blood was drawn between 8 and 9 a.m. Blood concentrations of SHBG was measured in nmol/L.", 
                "measure": "Other outcome was change in blood concentrations of SHBG (sex hormone-binding globulin).", 
                "safety_issue": "No", 
                "time_frame": "Patient's fasting blood was drawn at the base point and at the endpoint of 12 weeks of clinical trial."
            }, 
            {
                "description": "Patient's blood was drawn between 8 and 9 a.m. Blood concentrations of DHEAS was measured in micromol/L.", 
                "measure": "Other outcome was change in blood concentration of DHEAS (dehydroepiandrosterone sulfate).", 
                "safety_issue": "No", 
                "time_frame": "Patient's fasting blood was drawn at the base point and at the endpoint of 12 weeks of clinical trial."
            }
        ], 
        "overall_official": {
            "affiliation": "University Medical Centre Ljubljana", 
            "last_name": "Andrej Janez, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Slovenia: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The patient's body weight was measured in kilograms.", 
            "measure": "The main outcome was change in body weight.", 
            "safety_issue": "No", 
            "time_frame": "Patient's body weight was mesured at the base point and every four weeks during 12 weeks of clinical trial."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02037672"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Medical Centre Ljubljana", 
            "investigator_full_name": "Andrej Janez", 
            "investigator_title": "professor, MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Patient's BMI was defined as the patient's body mass in kilograms divided by the square of their height in meters.", 
                "measure": "The secondary outcome was change in body mass index (BMI).", 
                "safety_issue": "No", 
                "time_frame": "Patient's body weight were measured at the basepoint and every four weeks during the 12 weeks of clinical trial. Patient's height was measured at the basepoint."
            }, 
            {
                "description": "Patient's waist circumference was measured in centimeters.", 
                "measure": "The secondary outcome was change in waist circumference.", 
                "safety_issue": "No", 
                "time_frame": "Patient's waist circumference was measured at the basepoint and every four weeks during 12 weeks of clinical trial."
            }
        ], 
        "source": "University Medical Centre Ljubljana", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Medical Centre Ljubljana", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}